![William Polvino](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
William Polvino
Direttore/Membro del Consiglio presso SAB BIOTHERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
William J.
Polvino is currently the Chief Executive Officer & Director at Bridge Medicines LLC since 2017.
He is also the Director at SAB Sciences, Inc. since 2019 and the Independent Director at SAB Biotherapeutics, Inc. since 2021.
Previously, Dr. Polvino served as the President & Chief Executive Officer at Sapphire Therapeutics, Inc. from 2002 to 2009 and at Veloxis Pharmaceuticals A from 2011 to 2015.
He also held positions at Helsinn Therapeutics (U.S.), Inc., Big Cypress Acquisition Corp., Merck & Co., Inc., and Innoviva, Inc.Dr. Polvino holds a doctorate degree from the University of Medicine & Dentistry of New Jersey and an undergraduate degree from Boston College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
13/05/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di William Polvino
Società | Posizione | Inizio |
---|---|---|
SAB BIOTHERAPEUTICS, INC. | Direttore/Membro del Consiglio | 22/10/2021 |
Bridge Medicines LLC
![]() Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Amministratore Delegato | 27/03/2017 |
SAB Sciences, Inc.
![]() SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Direttore/Membro del Consiglio | 01/01/2019 |
Precedenti posizioni note di William Polvino
Società | Posizione | Fine |
---|---|---|
VELOXIS PHARMACEUTICALS A/S | Amministratore Delegato | 10/12/2015 |
Sapphire Therapeutics, Inc.
![]() Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Presidente | 01/01/2009 |
BIG CYPR | Direttore/Membro del Consiglio | - |
Helsinn Therapeutics (U.S.), Inc.
![]() Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Amministratore Delegato | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Formazione di William Polvino
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Boston College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
INNOVIVA, INC. | Health Technology |
SAB BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Sapphire Therapeutics, Inc.
![]() Sapphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sapphire Therapeutics, Inc. develops biopharmaceutical products. It develops compounds for the treatment of oncologic and metabolic diseases. The firm products include anamorelin for the treatment of anorexia and cachexia. The company was founded in 2000 and is headquartered in Bridgewater, NJ. | Health Technology |
Veloxis Pharmaceuticals A/S
![]() Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Helsinn Therapeutics (U.S.), Inc.
![]() Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ. | Health Technology |
Bridge Medicines LLC
![]() Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
SAB Sciences, Inc.
![]() SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Health Technology |
Big Cypress Acquisition Corp.
![]() Big Cypress Acquisition Corp. Financial ConglomeratesFinance Big Cypress Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on November 12, 2020 and is headquartered in Miami Beach, FL. | Finance |
- Borsa valori
- Insiders
- William Polvino